Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 4Recruiting 3Withdrawn 1Suspended 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 28Neoplasms 26Prostatic Neoplasms 22Colorectal Neoplasms 17Head and Neck Neoplasms 14Pancreatic Neoplasms 11Lung Neoplasms 10Brain Neoplasms 10Neoplasm Metastasis 9Carcinoma, Renal Cell 9Squamous Cell Carcinoma of Head and Neck 8Melanoma 8Carcinoma, Non-Small-Cell Lung 8Triple Negative Breast Neoplasms 7Recurrence 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Multiple Myeloma 7Lymphoma 7Glioblastoma 7Ovarian Neoplasms 6Lymphoma, Follicular 6Uterine Cervical Neoplasms 5Urinary Bladder Neoplasms 5Lymphoma, B-Cell 5Leukemia, Myeloid, Acute 5Leukemia 5Kidney Neoplasms 5Hematologic Neoplasms 5Sarcoma 4Liver Neoplasms 4

Interventions

tazemetostat 1etoposide phosphate 1Vincristine 1Prednisone 1Prednisolone 1Melphalan 1Etoposide 1Doxorubicin 1Cytarabine 1Cyclophosphamide 1Carmustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Enteropathy-Associated T-Cell Lymphoma × 1 year × Clear all
NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡